T. Rowe Price Associates
KMTS

T. Rowe Price Associates’s Kestra Medical Technologies KMTS Stock Holding History

T. Rowe Price Associates’s Portfolio KMTS Stock Details KMTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$126M Sell
4,968,900
-999,764
-17% -$20.9M 0.01% 634
2026
Q1 		$119M Buy
5,968,664
+1,599,235
+37% +$37.7M 0.01% 581
2025
Q4 		$116M Buy
4,369,429
+2,529,851
+138% +$65.2M 0.01% 600
2025
Q3 		$43.7M Buy
1,839,578
+842,382
+84% +$15.1M ﹤0.01% 845
2025
Q2 		$16.5M Buy
997,196
+147,778
+17% +$3.23M ﹤0.01% 1000
2025
Q1 		$21.2M Buy
+849,418
New +$19.5M ﹤0.01% 940

Other funds holding KMTS

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates's KMTS Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Kestra Medical Technologies (KMTS) stake by 17% in Q2 2026, selling an estimated $20.9M and leaving 4,968,900 shares worth $126M. The position accounts for 0.01% of the portfolio, ranked #634.

T. Rowe Price Associates first reported a position in KMTS in Q1 2025 and has held it in 6 quarters since. 108 funds tracked by Wall St. Rank hold KMTS as of Q2 2026.

  • T. Rowe Price Associates held 4,968,900 shares of Kestra Medical Technologies worth $126M as of Q2 2026.
  • T. Rowe Price Associates sold 999,764 Kestra Medical Technologies shares in Q2 2026, an estimated $20.9M.
  • Kestra Medical Technologies made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #634 holding.
  • T. Rowe Price Associates first reported a position in Kestra Medical Technologies in Q1 2025 and has held it in 6 quarters since.
  • 108 funds tracked by Wall St. Rank held Kestra Medical Technologies as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.